Full guideline Scope and Purpose

Background
Prescribing of anti-rheumatic and immunosuppressive drugs in women with rheumatic disease is often required to ensure adequate control of maternal disease activity and satisfactory pregnancy outcome. These drugs may also be required to control disease activity in men with rheumatic disease wishing to father a child. However, prescription of many of these drugs is complicated by concerns regarding their safety. These concerns arise from safety information based mainly on experimental and animal studies. Human data are limited to inadvertent exposure described in case reports/series and population registries. This ad hoc system of reporting has identified obvious risks with some anti-rheumatic drugs and led to uncertainty and theoretical concerns for others, such as LEF and biologics. Consequently, withdrawal or denial of disease-ameliorating therapies often occurs because of a perceived rather than proven risk of their lack of safety in pregnancy. It is important to avoid this situation, because active rheumatic disease is associated with adverse pregnancy outcomes [1] , and there is growing evidence of drug safety in pregnancy.
Need for guidelines
A previous survey based on a consensus workshop of international experts discussing the effects of anti-inflammatory, immunosuppressive and biologic drugs during pregnancy and breastfeeding has made recommendations for drug treatment during pregnancy and breastfeeding [2] . These recommendations were made by analysing information published prior to 2006 and updated for biologics with information published in 20067 [3] . However, formal guidelines are currently lacking on this topic and the question of whether biologics are safe to prescribe in pregnancy and/or breastfeeding is increasingly being asked. Therefore, guidelines are urgently required for medical professionals across the country to have a consistent approach to prescribing anti-rheumatic drugs before/during pregnancy and breastfeeding.
Objectives of the guideline
To expand and update the previous consensus recommendations (20068) and systematically review all current evidence to answer specific questions in relation to each drug as follows. Should it be stopped pre-conception? Is it compatible with pregnancy? Is it compatible with breastfeeding? Where possible, recommendations are made regarding compatibility with paternal exposure.
Target audience
The primary audience consists of health professionals in the UK directly involved in managing patients with rheumatic disease who are (or are planning to become) pregnant and/or breastfeeding, men planning to conceive and patients who have accidentally conceived while taking these medications. This audience includes rheumatologists, rheumatology nurses/allied health professionals, rheumatology speciality trainees and pharmacists, as well as the patients themselves. The guideline will also be useful to obstetricians, obstetric physicians, renal physicians and general practitioners who prescribe these medications in pregnancy.
The areas the guideline does not cover This guideline does not cover the management of infertility or the indications for these drugs in specific rheumatic diseases in pregnancy. Gold and penicillamine were not included in the search, as these drugs are rarely used in rheumatology practice and thus do not tend to be encountered in patients of childbearing age.
identified by searching Medline and Embase databases using combinations of the key MESH and free terms: pregnancy, lactation, breastfeeding, name of each drug and name of key rheumatic diseases. The full electronic search strategies for Medline and Embase databases are shown in the search strategies appendix. Additional published studies were identified through the Cochrane, LactMed (a National Library of Medicine database on drugs and lactation) and UK Tetralogy Information Service (UKTIS) databases, communication with pharmaceutical companies on the relevant biologics, checking the reference lists and other author publications of articles selected for full-text analysis. At least two independent reviewers screened the title and abstract of retrieved articles to identify studies that met inclusion criteria of randomized and non-randomized controlled trials, cohort studies, casecontrol studies and case series/reports. Animal studies, abstracts and non-systematic reviews were excluded from the final analysis. Disagreements were resolved by group discussion.
A data extraction sheet was developed and its reliability examined on 10 randomly selected studies. It was then refined accordingly to ensure that relevant data from these studies on pregnancy exposure and related outcomes was captured using the data extraction sheet available in the appendix.
Statement of extent of National Institute for Health and Care Excellence, Royal College of Physicians, Scottish Intercollegiate Guidelines Network guidelines
There are no British Society of Rheumatology (BSR), National Institute for Health and Care Excellence (NICE), Royal College of Physicians (RCP) or Scottish Intercollegiate Guidelines Network (SIGN) guidelines for prescribing in rheumatic disease in pregnancy. EULAR guidelines on prescribing of selected anti-rheumatic drugs in pregnancy are currently in development.
Statement of methods used to formulate the recommendations (levels of evidence)
This guideline was developed in line with BSR's Guidelines Protocol using RCP, SIGN and Appraisal of Guidelines, for Research, and Evaluation II (AGREE II) methodology to determine the level and strength of evidence. The working group met regularly to formalize the search strategy, review evidence, resolve disagreements and, finally, to determine recommendations. The wording of each suggested recommendation was agreed by all members (580% was taken as consensus) and subjected to a vote relating to SOA on a scale of 1 (no agreement) to 10 (complete agreement).
The recommendation statements are presented at the end of each drug section, which includes the relevant references selected from our systematic search (see Tables 14) . For drugs where important papers were published after our final search date and/or information was particularly lacking, additional data derived from these papers and relevant conference abstracts are described in the main text but these data were not included in the final grading of each recommendation, unless there was no other information available. Accompanying each recommendation statement in brackets is the highest level of evidence (LOE) and the grade of recommendation (GOR) based on the body of available evidence, according to SIGN [5] , followed by a percentage showing the SOA from voting of all 19 group members. The level of evidence for recommendations from the previous consensus review [2] are shown as a Roman numeral, derived from Miyakis et al. [6] , which was taken into account in the final GOR and shown only where additional data were lacking. Where no evidence was found and no expert opinion was formed, recommendations were left ungraded.
Statement of any limits of the search and when the guideline will be updated
The search was conducted in June 2012 and updated in December 2013. Inclusion criteria were English language and date of publication to avoid overlap with drugs previously reviewed by Ostensen et al. [2, 3] . Searches relating to the use of drugs in pregnancy and breastfeeding in the absence of rheumatic disease excluded publications with fewer than five patients. The guideline will be updated in 3 years.
The guideline
Eligibility criteria
This guideline is intended for use by healthcare professionals who are currently (or considering) treating women who are planning pregnancy, currently pregnant or breastfeeding with any of the drugs listed in this document. Recommendations for men trying to conceive on these drugs are also given where sufficient evidence is available.
Exclusion criteria
Infertility and animal studies were excluded from the analysis. Gold and penicillamine were excluded because they are not commonly used and there has been no new information on their use in pregnancy and breastfeeding since the last consensus review [2] . A flow diagram of study selection is shown in Fig. 1 , displaying the initial number of articles screened, the number of articles selected for full-length review and the number included in the final analysis.
Treatment
Drugs are considered by categories. This part of the guideline, part 1, considers antimalarials, corticosteroids, DMARDs and immunosuppressive therapies and biologics. Part 2 of this guideline considers pain management, NSAIDs and low-dose aspirin, anticoagulants in the management of multisystem rheumatic disease, bisphosphonates, anti-hypertensive medication in the management of multisystem rheumatic disease and pulmonary vasodilators [7] . The findings for each drug are presented as follows: type of study selected, number of www.rheumatology.oxfordjournals.org pregnancy exposures, pregnancy duration, birthweight, maternal complications, miscarriages, number and types of congenital anomalies, breastfeeding, long-term followup, paternal exposure and recommendations. Where possible, congenital anomalies described in original publications were classified as major or minor according to European Surveillance of Congenital Anomalies (EUROCAT) definitions [8] . An overall summary of compatibility of each drug pre-conception, during pregnancy, during breastfeeding and paternal exposure is shown in Table 1 . Evidence summarizing the total number of pregnancies following maternal exposure to each drug is shown in Tables 2 and 3 and, where reported, outcomes of miscarriage, live births and major anomalies are summarized. Outcomes following paternal exposure are shown in Table 4 . To reduce the impact of publication and selection bias, only papers with at least five patients are included in Tables 24. Other papers included in our search that do not meet these criteria are discussed in the main text.
Corticosteroids
Corticosteroids used to treat rheumatic disease (prednisolone, prednisone and methylprednisolone) are metabolized in the placenta, so 410% of the active drug reaches the foetus, and they are considered to be compatible with pregnancy and breastfeeding [2] . We identified a number of additional studies from 2005 onwards: 47 on prednisolone (n = 1503 pregnancies) [78, 92] , 14 cohort studies [63, 64, 66, 68, 69, 93101 ] and 1 case report [82] ; and 10 on general corticosteroids (n = 785 pregnancies) comprising 1 RCT [102] , 4 cohort studies [103106] , 2 case series [80, 107] and 3 case reports [108110] . The studies were confounded by multiple concomitant medications and use in high-risk pregnancies, particularly the fluorinated steroids, which are used to prevent or treat preterm labour and complications such as foetal lung immaturity.
Studies on the use of methylprednisolone in pregnancy were not specifically sought because it is generally used as rescue therapy for severe disease. Compared with prednisolone, parenteral administration of methylprednisolone has a prolonged duration of action, with equivalent glucocorticoid (anti-inflammatory) effects at 80% of the prednisolone dose with similar rates of placental transfer to prednisolone [111] .
Following prednisolone (or unspecified corticosteroid) exposure, the average pregnancy duration in the majority of RCTs, casecontrol, cohort and case series studies (where reported) was usually term, at >37 weeks [11, 12, 14, 16, 20, 24, 27, 29, 35, 36, 38, 39] . The exceptions were studies of prednisolone use in patients with haemolysis, elevated liver enzymes and low platelets, where gestation averaged 2829 weeks [13, 15] ; a study of corticosteroid use in the management of pre-eclampsia [102] ; one case series of renal transplant patients on MMF averaging 34 weeks [33] ; one case series (n = 8) of ulcerative colitis patients being treated for a flare with corticosteroids as well as CSA [and AZA/infliximab (IFX) in some cases], where the average duration was 36 weeks [107] ; and one cohort study reporting on 152 RA patients, of whom 56 were taking prednisolone during pregnancy, where a subanalysis demonstrated an association between prednisolone usage and reduced gestational age at delivery [23] . In contrast, in case reports describing preterm deliveries at <34 weeks, the reduction in gestational age was confounded by active disease, mainly SLE [44, 46, 55] and one case of active SS with acute mesangial proliferative glomerulonephritis and vasculitis [40] , or concomitant drugs such as MMF [43, 44, 46, 50] .
Studies of dexamethasone were particularly confounded by its use in haemolysis, elevated liver enzymes and low platelet count syndrome and/or pre-eclampsia, with preterm deliveries almost universally reported (attributable to the pregnancy complication rather than the steroid administration). In contrast, a systematic review of labour induction in 33 post-term mothers with pregnancies exposed to dexamethasone averaged 41 weeks [60] . Similarly, studies of betamethasone were confounded by its use in preterm birth to reduce respiratory distressrelated morbidity, and the average pregnancy duration from all studies ranged from 32 to 37 weeks. Therefore, it is impossible to draw conclusions from these studies as to an effect of either dexamethasone or betamethasone on pregnancy duration.
Birthweights followed a similar pattern and were affected by preterm deliveries and the confounding factors www.rheumatology.oxfordjournals.org described above. For instance, in those RCTs, cohorts, casecontrol studies and case series with prednisolone exposure that reported average gestations of >37 weeks, average birthweights ranged from 2.6 to 3.4 kg [12, 14, 16, 20, 23, 24, 27, 29, 35, 38, 39] . Overall, prednisolone itself was not felt to have contributed to low birthweight (LBW) in any study. The studies of dexamethasone and betamethasone revealed LBW in preterm deliveries with confounding comorbidity. Only one study [69] attributed LBW to fluorinated steroids, with significantly higher rates of intra-uterine growth restriction and premature rupture of membranes in the exposed group, with the risks of treatment after 34 weeks outweighing the benefits. Reduced birthweight, particularly with betamethasone, was noted in an RCT examining neonatal respiratory distress syndrome after repeat exposure to fluorinated steroids [88] . However, further evaluation of this cohort showed accelerated post-natal growth at 35 weeks [101] .
High rates of maternal complications compatible with underlying disease were reported for prednisolone and dexamethasone, but none were specifically attributed to these medications. In contrast, an increased incidence of chorioamnionitis was reported with betamethasone exposure compared with drug-free controls in a study of tocolysis [57] .
The major congenital malformations observed with prednisolone were frequently confounded by concomitant teratogenic drug exposure, for example, MMF [54] , and the overall incidence was not significantly higher than in drug-free controls. Several studies reported major malformations with fluorinated steroid exposure, for example, patent ductus arteriosus, blindness and deafness [64, 84] , although none of them were deemed attributable to steroid therapy by the authors. Furthermore, in the majority of cases the steroids were used for the treatment of underlying conditions such as preterm delivery [64] , where steroids were found to be beneficial in improving 2 cc [13, 103] Overall no increase in rate of major malformations attributable to drug 10 ct [16, 19, 20, 22, 25, 102, 104, 121123] 3 cs [30, 79, 124] 1cc [129] There is no evidence upon which to recommend GOL, but it is unlikely to be harmful in the first trimester Infliximab 5 ct [102, 193196] 8 cs [130, 197203] 265, first 591, second/third
No significant adverse effect noted 0/76 in two cohort studies and four case series [194, 195, 197, 199, 201, 203 Where possible, the number of births and pregnancy outcomes related to individual drug exposures is reported. Most reports are from cohort studies examining multiple drug exposure outcomes, from which the number of specific outcomes could not be extracted, but in which no overall increase in adverse outcomes compared with the general population was reported. Details of how numerical data shown in this outcomes, or treatment of maternal autoantibodymediated cardiomyopathy [71] . The evidence is also reassuring with regards to cleft palate: two instances of cleft palate were reported from 82 pregnancies, but in neither case was the anomaly attributed to steroid exposure [12, 24] . Furthermore, a large study analysing 832 636 live births did not show an increased risk of orofacial cleft palate with the use of corticosteroids in pregnancy [106] .
Foetal loss in studies of prednisolone and fluorinated steroids was attributed to underlying disease rather than steroid therapy, such as in APS [38] and complete atrioventricular (AV) block [112] . There were few breastfeeding studies on which to base conclusions. An analysis of 320 milk samples from 46 mothers identified a significant delay in the onset of breastfeeding, which may have been compounded by betamethasone exposure in extremely preterm babies [95] . The nursing infant receives only 10 mg/kg even at a maternal prednisolone dose of 80 mg/day [2], ensuring low prednisolone exposure to breastfed infants, although it would seem prudent to restrict the maternal dosage to the minimum possible.
In long-term follow-up studies, no adverse events were reported after prednisolone exposure in pregnancy. In particular, no evidence of immune dysfunction was found 12 months post-partum [14] . Two systematic reviews evaluating the effects of prenatal exposure to fluorinated steroids in mothers at risk of preterm delivery from 20 different studies reported neurosensory disability in 139 of 6811 (2%) preterm deliveries ranging from 24 to 35 weeks duration [56, 84] . Although there were no control data for comparison in these studies, early childhood follow-up from four studies showed no substantive differences in children exposed to repeat prenatal corticosteroids compared with unexposed children for survival or neurosensory disability at 18 months2 years corrected age [56, 64, 84, 100] . A recent cohort study [100] showed no adverse effect on psychological health in the long-term, but a possible impact on aspects of executive functioning.
Paternal exposure
Four cohort studies [21, 113115] and two case series [116, 117] reported on outcomes from pregnancies (at least n = 2127) after paternal exposure to prednisolone and a casecontrol study [118] and a case series [119] reported on outcomes from pregnancies (n = 4) after paternal exposure to methylprednisolone. Overall, the quality of these studies was low, but reassuringly, they did not identify an increased risk of adverse foetal outcomes.
Recommendations for corticosteroids in pregnancy and breastfeeding (i) Prednisolone is compatible with each trimester of pregnancy and is the preferred corticosteroid in the treatment of maternal rheumatologic disease in pregnancy (LOE 1 ++, GOR A, SOA 100% [20, 23, 124] . No specific pattern of congenital malformations was observed in association with HCQ exposure. A total of 14 of 192 (7.3%) first trimester miscarriages were reported. One study followed 15 children for up to 12 months post-partum and found no differences in immune function in terms of absolute lymphocyte count, percentage of B and T lymphocytes and immunoglobulin production compared with women with rheumatic diseases not exposed to drugs in pregnancy [14] . Overall, these studies included relatively large numbers of patients, with generally good outcomes except in case reports. There were no new studies published in the time period of our search on outcomes of infants exposed to HCQ in breastfeeding. Given that the half-life of HCQ is >40 days [128] , all infants exposed to HCQ throughout pregnancy will also have been exposed during breastfeeding, and there is no evidence that this exposure is harmful. Case reports identified in the previous consensus found that when breastfeeding is continued, <1% of the maternal dose of HCQ was found in breast milk [2] .
A study published after our final search, of 194 firsttrimester exposures to HCQ did not identify a significant increase in the risk of congenital malformations, foetal death or neonatal complications in pregnancies of women with chronic autoimmune disease compared www.rheumatology.oxfordjournals.org with those who received HCQ before but not during pregnancy [128] .
A cohort study [20] and a case series [117] reported on outcomes from 13 pregnancies after paternal exposure to HCQ. In this small number of exposures, no increased risk of adverse foetal outcomes was observed.
Recommendations for HCQ in pregnancy and breastfeeding 
DMARDs and immunosuppressive therapies
MTX MTX is contraindicated in pregnancy and recommended to be stopped 3 months in advance of conception [2] . The UKTIS considers MTX risk in pregnancy to be dependent on its use at high (>20 mg/week) or low (420 mg/week) dosage. In general, the use of MTX to treat inflammatory arthritis falls into the low-dose category and is far removed from the high doses used as a chemotherapeutic agent in the treatment of various cancers, for example, >500 mg/m 2 , or as an abortifacient at 50 mg/m 2 . The UKTIS reports that teratogenic insult caused by MTX has not been observed at doses of < 10 mg/week in pregnancy, although the number of case reports from which these data were taken remains too small to identify a safe weekly dose of MTX. Based on current information, the UKTIS found it difficult to draw conclusions about the exact risks high-dose MTX administration poses to a developing foetus. In a significant proportion of the reports, even though high doses were administered in the first trimester, infants were born without evidence of congenital malformations. However, reports exist that suggest an association with first-trimester MTX exposure and a consistent pattern of malformation (MTX embryopathy) in both newborn infants and spontaneously aborted foetuses.
Since the previous consensus, we identified MTX exposure predominantly during the first trimester of pregnancy in 27 pregnancies from three cohort studies [21, 22, 103] , one casecontrol study [130] , one case series [131] and five case reports [132136] . Confounding factors included concomitant treatment with other DMARDs (such as LEF and MMF), steroids and anti-TNF therapies. Pregnancy duration was reported in five patients with SLE, of whom three [131, 132, 136] were term (>39 weeks) while two were premature at 31 and 34 weeks with corresponding LBWs of 1.7 and 2.2 kg [134, 135] .
No maternal complications were reported. A total of 10 live births were reported for MTX (dose not stated) used in the first trimester of pregnancy [22, 131, 132, 134136] . There were four cases with major anomalies, including ventricular septal defect and hydronephrosis [132, 135] and two other cases of major malformations described in patients with SLE taking concomitant MMF [134, 135] . Five minor malformations were described, but no significant patterns emerged. Two first-trimester spontaneous pregnancy losses occurred in patients with RA on concomitant therapy with IFX and abatacept (ABA). There were no studies of breastfeeding. Two cases reported long-term follow-up of 2.8 and 14 months, respectively, in which both had long-term complications of semilobar holoprosencephaly, tracheostomy and requirement for antiepileptic therapy [134, 135] . There were no studies included in our search examining the safety of breastfeeding on MTX.
Three studies published after our final search date provide further information on 367 pregnancies exposed to MTX. Analysis of 23 first-trimester exposures to low-dose MTX identified from three US health plan databases did not reveal a significant increase in the risk of congenital malformations, foetal death or neonatal complications in women with chronic autoimmune disease compared with those who received MTX before but not during pregnancy [129] . Examination of data from the National Birth Defects Prevention Study, a US casecontrol study of major birth defects, identified 4 of 10 113 (0.04%) mothers of foetuses or infants without major birth defects had been exposed to MTX compared with 16 of 27 623 (0.06%) mothers of live-born infants with a major birth defect who had been exposed to MTX [137] . The dose of MTX was not reported, but indications included a neoplasm of endocrine glands, so it was presumably of high dose in at least one case. Of the 16 cases with major birth defects, 15 were exposed from 3 months pre-conception to the end of the first trimester. A large prospective observational multicentre cohort study of 324 pregnancies exposed to MTX found an increase in cumulative incidence of spontaneous abortion (42.5%) and major congenital anomalies (6.6%) among 188 pregnancies exposed to a median dose of 10 mg/week MTX a median of 4.3 weeks after conception [138] . This difference reached statistical significance when compared with a cohort of women without autoimmune diseases, but not when compared with a diseasematched cohort. In contrast, an increased risk of miscarriage or major congenital anomaly was not found in 136 pregnancies exposed to a median dose of 15 mg/week of MTX that was stopped 3 months pre-conception. Therefore, the conclusion of this study was that a 3-month MTX-free interval prior to conception might not be required.
Paternal exposure
MTX does not impair male fertility [2] . Four cohort [21, 113, 115, 139] , three case series [117, 119] and a case report [140] described outcomes from 263 pregnancies after paternal exposure to predominantly low-dose MTX. Overall, the quality of these studies was low, with information lacking from several studies primarily looking at the safety of other medications. However, a large study published after our final search date of 113 pregnancies after paternal exposure to low-dose MTX did not identify an increased risk of adverse foetal outcomes compared with 412 non-exposed pregnancies [139] . 
SSZ
The previous consensus determined that SSZ is compatible with pregnancy and breastfeeding and can be continued with adequate folate supplementation (5 mg/day).
[2] This recommendation was based on six casecontrol/ population studies, which did not find any adverse effects of SSZ on 675 pregnancy outcomes in patients with IBD, where it is used at a maintenance dose of 23 g/day and 48 g/day during disease flares. In addition, it was recommended that maternal doses of SSZ should not exceed 2 g/day based on a case report of neutropenia in a newborn infant [141] . The use of SSZ in the management of IBD in pregnancy is well established and was recently reviewed by Vermeire et al. [142] . We identified three additional cohort studies [21, 23, 103], a case series [31] and two case reports [127, 143] on SSZ exposure in 178 pregnancies in patients with RA, osteoporosis and AS. These studies contained limited information relating to miscarriage rates, pregnancy duration, birthweight or malformation rates, but overall there were no significant adverse effects highlighted that were considered to be directly attributable to SSZ.
We did not identify any additional studies on the use of SSZ in breastfeeding. Minimal amounts of SSZ are expressed in breast milk and it can be used during breastfeeding if the infant is full term and healthy, although it should be avoided in ill, stressed or premature infants and in infants with hyperbilirubinaemia or glucose-6-phosphate dehydrogenase deficiency [2] .
Paternal exposure
Male fertility may be affected by SSZ. Oligospermia, reduced motility as well as an increased proportion of abnormal sperm forms have been noted in rats and men taking SSZ and is related to the sulphapyridine moiety of the drug [144] . In addition, a study of the effects of SSZ on 194 paternal exposures after diagnosis of IBD found that of 42 men who experienced a delay of >12 months in achieving conception, more than half (n = 22) reported taking SSZ [145] . This risk was potentially linked to the antagonistic effects of SSZ on folic acid metabolism and relative folic acid deficiency, which is reduced by concomitant folic acid supplementation [146] . Therefore the 2006 consensus recommended that patients wishing to father a child should be counselled to discontinue or not commence this drug for a minimum period of 3 months prior to trying for a baby, as the maturation of sperm takes 3 months [2] .
We identified three cohort [21, 115, 147] and one casecontrol study [118] reporting on outcomes from 237 pregnancies after paternal exposure to SSZ. Overall, no increased risk of adverse foetal outcomes was observed. However, the quality of evidence from these studies was low, with a lack of information on the medical history of fathers, concomitant therapy, compliance with prescribed medication, early first-trimester miscarriages and fertility.
Recommendations for SSZ in pregnancy and breastfeeding (i) SSZ with folate supplementation (5 mg/day) is compatible throughout pregnancy, and folic acid should be prescribed to women taking SSZ who are trying to conceive (LOE 2+, GOR C, SOA 100% [151, 152] and there was one case of low (2.5 kg) birthweight [152] . One prospective controlled study [148] did not show a significant increase in adverse pregnancy outcomes in 64 women on LEF, the majority of whom stopped the drug in the first trimester and were treated with cholestyramine, compared with control pregnancies (n = 108 pregnant women with RA not on LEF and n = 78 healthy controls). In particular, the number of major congenital anomalies (the definition of which fulfilled that for EUROCAT major anomalies) was not increased in the LEF-exposed group. Minor anomalies were defined as structural defects of no cosmetic or functional importance, occurring in <4% of the general population. Examples of these frequently subtle minor structural defects include a missing crease on one or more of the digits, a broad nasal bridge, protruding earlobes or a relatively indistinct philtrum of the upper lip, thus they do not all meet EUROCAT definitions of minor anomalies. Reassuringly, despite the finding of a higher proportion of children in the LEF-exposed group with minor anomalies (n = 51 in total) than in the two control groups, this difference did not reach statistical significance (P = 0.1) and no specific pattern of three or more anomalies was found in LEF-exposed children.
A later smaller cohort study comparing 16 women exposed to LEF during pregnancy with 29 women exposed to LEF <2 years prior to pregnancy [22] found major congenital anomalies in two infants born to LEF-exposed pregnancies and none in those exposed prior to pregnancy. None of these specific defects were reported in the previous cohort study [148] . In addition, there was a potential known alternative aetiology (including spontaneous death of a twin and maternal disease) unrelated to LEF exposure in each case. Minor anomalies were recorded in the same way as the previous cohort study and 35 infants were examined. The frequency of infants with at least three minor anomalies was similar in the two groups, involving seven (50%) infants examined in the during-pregnancy exposure group and nine (42.9%) infants examined in the pre-conception exposure group. No specific pattern of abnormalities was observed and the spontaneous abortion rate was within the normal range seen in the general population [22] . There were no data on breastfeeding.
A cohort [21] and case report [153] described outcomes from two pregnancies after paternal exposure to LEF within 3 months of conception and subsequent pregnancy exposure (with intercourse without a condom) in at least one case with no reported washout. No adverse foetal outcomes were observed. 
AZA
The previous consensus reported on seven studies with 405 pregnancies with maternal exposure to AZA or its active metabolite 6-mercaptopurine (6-MP) and concluded that AZA is compatible with pregnancy, but there is a lack of consensus on its use in breastfeeding given a theoretical risk of immunosuppression, carcinogenesis and growth restriction in the infant [2]. Two of these seven studies noted a relationship between the dose of AZA and birth abnormalities, as well as depressed haematopoiesis in pregnancies whose mothers were treated with >2 mg/kg AZA daily [154, 155] . An additional 28 studies were identified relating to the use of AZA in pregnancy and breastfeeding. Of these studies, 24 included pregnancy outcome data [10, 16, 1921 [157] , whereas average weights for 389 control pregnancies ranged from 3 [33] to 3.5 kg [16] . Reporting of maternal complications in these studies was limited and no firm conclusions can be drawn due to the likelihood of confounding of pregnancy outcomes by underlying diseaseand pregnancy-related complications.
In 238 AZA-exposed pregnancies [10, 25, 36, 123, 156, 158, 161], 13 major malformations were recorded. Overall, there was no indication of an increased rate or specific phenotype of congenital malformations due to AZA above the background population. In addition, there was no indication of increased first-trimester losses among AZAexposed pregnancies compared with controls. Two second-/third-trimester losses were reported in 5 AZAand corticosteroid-exposed pregnancies in a larger cohort study of mothers with pemphigus vulgaris, compared with none in 405 control pregnancies, but these deaths were attributed to foetal pemphigus in one pregnancy and CMV infection in the other [10] .
Four studies directly addressed the safety of AZA in pregnancy. One study followed 30 children exposed to thiopurines in utero for up to 6 years post-partum and found no effect on long-term development or immune function [159] . Another study of 189 women exposed to AZA in pregnancy compared with 230 drug-free controls concluded that there was no increase in birth defects, but exposure was associated with lower birthweights and prematurity [156] . A study of 19 births exposed to AZA compared with 74 controls did not detect any increase in congenital anomalies and did not find any association with increased risk of preterm birth, LBW at term or adverse neonatal outcomes [158] . A study of 187 IBD pregnancies exposed to thiopurines alone compared with 29 exposed to TNF-a inhibitors (TNFis), 37 exposed to both and 318 unexposed disease controls found that the use of thiopurines was associated with a favourable global pregnancy outcome [130] .
A total of 26 infants breastfed by mothers on AZA or its active metabolite 6-MP were identified. One study of eight AZA-exposed mothers found that 6-MP was predominantly excreted into breast milk within 4 h of maternal ingestion, and based on the maximum concentration measured, infant ingestion of 6-MP was <0.008 mg/kg/ 24 h [162] . An analysis of 31 breast milk samples from 10 AZA-exposed mothers revealed detectable concentrations of 6-MP at 3 and 6 h after ingestion in 2 samples from a single infant but was undetectable in the other 29 samples [163] . Furthermore, 6-MP and its metabolites-6-thioguanine nucleotides-were undetectable in neonatal blood and there were no clinical or haematological signs of immunosuppression in the 10 neonates studied [163] . In a study of four women treated with AZA during breastfeeding, 6-MP concentration measured in the milk of two mothers revealed an absolute relative infant dose <0.09% of the maternal weight-adjusted dose and no adverse events occurred in any of the four infants [35] . In a case series of four infants exposed to AZA in breast milk, neither 6-MP nor 6-thioguanine nucleotides was detected in any of the infants [164] .
Paternal exposure
Six cohort studies [21, 113115, 165, 166] , a casecontrol study [118] and two case series [116, 117] reported on outcomes from 602 pregnancies after paternal exposure to AZA. Overall, no increased risk of adverse foetal outcomes was observed.
Recommendations for AZA in pregnancy and breastfeeding 
CSA
More than 800 human pregnancies exposed to CSA were reviewed in the previous consensus and it was considered compatible with pregnancy at the lowest effective dose with monitoring of blood pressure and renal function [2]. These recommendations were based on evidence of compatibility mostly from pregnancies in transplant recipients treated with a maintenance dose of 26 mg/kg/day and reports of embryotoxicity in animal pregnancies at high dosages of 25100 mg/kg/day. A search from 2005 onwards identified an additional four casecontrol studies [14, 16, 73, 74] , five cohort studies [20, 24, 25, 28, 103] , three case series [35, 80, 107] and a case report [167] (studying the effect of breastfeeding) of 98 pregnancies in patients with a variety of different diseases [including IBD, solid organ transplantation and autoimmune rheumatic disease (ARD)] and multiple concomitant medications exposed to CSA at 26 mg/kg during pregnancy. Pregnancy duration was quantified in four studies (n = 23 pregnancies) and the average ranged from 35.3 to 38 weeks [24, 35, 74, 107] . The average birthweight was reported in exposed pregnancies in three studies as low (n = 1) [16] , 2.3 kg (n = 11) [24] and 2.9 kg (n = 8) [107] . In contrast, an average birthweight of 3.5 kg (n = 80) [16] and 3.1 kg (n = 15) [14] was reported in control groups.
Multiple maternal complications and two stillbirths were described in 11 women on CSA after renal transplantation [24] . A second-/third-trimester foetal death occurred in a mother with protein S deficiency in a case series of eight www.rheumatology.oxfordjournals.org pregnancies in eight patients with ulcerative colitis [107] . Malformations were quantified in 26 pregnancies in two studies [28, 107] and two major malformations were reported, but these pregnancy outcomes were confounded by concomitant treatment with either AZA or MMF [28] .
The previous consensus described findings from several case reports and case series that found small amounts of CSA in breast milk and almost universally undetectable blood levels in infants [2] . We found one further study specifically examining breastfeeding in a renal transplant recipient on 2.1 mg/kg/day CSA (as well as AZA 0.9 mg/kg and prednisolone) in whom subtherapeutic blood levels and lower levels in breast milk were detected at a mean milk to maternal blood concentration of 0.94, with undetectable blood levels in the infant [167] . No adverse effects during breastfeeding were reported in this study. Longterm follow-up of 10 infants exposed to CSA in utero revealed no complications at 1114 months [14, 73, 80] .
Paternal exposure
Two cohort studies [114, 168] and two case series [116, 119] reported on outcomes from at least 254 pregnancies after paternal exposure to CSA. Overall, the quality of these studies was low, but they did not identify an increased risk of adverse foetal outcomes.
Recommendations for CSA in pregnancy and breastfeeding (i) CSA is compatible throughout pregnancy at the lowest effective dose with suggested monitoring of maternal blood pressure, renal function, blood glucose and drug levels. (LOE 1, GOR B, SOA 100%).
(ii) Mothers on CSA should not be discouraged from breastfeeding (LOE 3, GOR D, SOA 100%).
(iii) Based on limited evidence, CSA is compatible with paternal exposure (LOE 2À, GOR D, SOA 98.9%).
Tacrolimus
Tacrolimus was considered compatible with pregnancy and breastfeeding in the previous consensus [2, 3] . An additional seven studies were identified. Six of these studies (three cohort studies [24, 25, 169] , one case series [33] and two case reports [41, 54] ) included 26 pregnancies exposed to tacrolimus, as well as one pharmacokinetics study of drug levels in the umbilical cord and breast milk [169] . One cohort study addressed tacrolimus in breastfeeding only [170] . The largest study [24] included women after renal transplantation, one reviewed patients treated for autoimmune hepatitis [25] , one was a case report of a single patient with LN [41] and two studies addressed the effect of MMF where tacrolimus was used concomitantly in some pregnancies [33, 54] . There were complex confounding issues in all of these studies. The average pregnancy duration from the largest cohort study (n = 9) was 37 weeks, but included three premature deliveries, one case of intra-uterine growth restriction and one small-for-gestational-age infant [24] . Three other studies of five pregnancies (concomitant MMF in four of the five cases) reported preterm deliveries of 3035 weeks.
Maternal complications were considered to be related to maternal disease or concomitant medication. Three major congenital malformations were reported in two studies of MMF in pregnancy [33, 54] . In contrast, no major or minor malformations were reported in the remaining pregnancies reported following tacrolimus exposure. No spontaneous miscarriages were reported and one elective termination was carried out, where the pregnancy had concomitant MMF exposure. Overall, no increased risks were observed with exposure at conception or during pregnancy.
One study measured the mean umbilical cord venous plasma and unbound drug concentrations and found that they were approximately one-fifth of the respective maternal concentrations [169] . Infant exposure through breast milk was <0.3% of the mother's weight-adjusted dose in a single case in which tacrolimus pharmacokinetics was studied. A study [170] examining samples from 12 breastfed infants found that following delivery of babies exposed to tacrolimus in utero, blood levels of tacrolimus were not increased in breastfed compared with bottle-fed infants, with equal rates of elimination post-partum. The maximum estimated absorption from breast milk was 0.2% of the maternal weight-adjusted dose. Exposure to the drug during breastfeeding is relatively insignificant compared with exposure in utero, which has not been shown to be associated with any long-term adverse effects. A recent case series published after our final search reported the successful treatment of nine pregnant patients with LN, with no adverse effects on pregnancy duration or birthweight and no congenital abnormalities [171] .
Paternal exposure
Three cohort studies [114, 168, 172] reported on outcomes from >120 pregnancies after paternal exposure to tacrolimus. Overall, the quality of these studies was low, but they did not identify an increased risk of adverse foetal outcomes.
Recommendations for tacrolimus in pregnancy and breastfeeding 
CYC
CYC is a known human teratogen and is gonadotoxic in men and women [2] . In addition to a potential long-term impact on spermatogenesis (and hence fertility) in men [173] , there is evidence of male-mediated teratogencity from animal studies [174] , although this has not been proven in humans [175] . An additional case series [36] and four case reports [40, 48, 109, 110] of predominantly first-trimester use of CYC in nine pregnancies of mothers with severe maternal disease (mostly acute renal failure) were identified in patients with SS (n = 3) and SLE (n = 6) on concomitant medication including HCQ, AZA and prednisolone. In a case series (n = 5), the average pregnancy duration was 38 weeks [36] , and in three case reports it was 27, 28 and 40 weeks. One preterm birth occurred at 28 weeks in a patient with a new diagnosis of acute renal failure and SS in the second trimester of pregnancy who was treated with CYC, prednisolone and haemodialysis [40] . Birthweights were recorded in case reports and were appropriate for age in two preterm births (1.1 kg at 2728 weeks) [40, 110] , while a term delivery (40 weeks) was growth restricted at 1.8 kg in an infant with KlippelFeil syndrome [48] .
No maternal complications of CYC were reported. These nine pregnancies ended in two first-trimester miscarriages, six healthy infants and one major congenital anomaly (KlippelFeil syndrome). There were no breastfeeding studies. Follow-up to 8790 months in four live births reported normal development in three children [36] and the single case of KlippelFeil syndrome [48].
Paternal exposure
No further studies of paternal disease were identified.
Recommendations for CYC in pregnancy and breastfeeding (i) CYC is a known teratogen and gonadotoxic, therefore it should only be considered in pregnancy in cases of severe life-or organ-threatening maternal disease when there is appreciable risk of maternal and foetal morbidity and mortality without this therapy (LOE 2, GOR C, SOA 100%). (ii) There is no evidence to recommend the use of CYC in breastfeeding (LOE 4, GOR D, SOA 100%). (iii) Paternal exposure to CYC is not recommended (LOE 4, GOR D, SOA 98.4%)
MMF
MMF is a known teratogen and is recommended to be stopped at least 6 weeks before a planned pregnancy [2, 3] . It is rapidly absorbed following oral administration and hydrolysed to form the active ingredient mycophenolic acid. This active metabolite has a mean apparent halflife of 17 h after a 1 g oral dose of MMF and undergoes enterohepatic circulation with a secondary plasma peak at 612 h after an oral or i.v. dose [176] . Therefore, MMF is advised to be stopped at least 6 weeks before conception. An additional 2 cohort studies [24, 28] , 3 case series [33, 161, 177 ] and 11 case reports [43, 46, 50, 51, 54, 178183] including 90 pregnancies exposed to MMF were identified, mostly from renal transplant patients in whom there was concomitant exposure to prednisolone and tacrolimus. In the majority of cases, pregnancy duration was appreciably shortened to 2933 weeks in two cases [43, 182] and 3436 weeks in three cases [51, 54, 181] and one case series [33] and to preterm (<37 weeks) in one case series [177] , with only four term (>37 weeks) deliveries [161, 177, 178, 180] . There was a corresponding increased risk of LBW, with two cases <1 kg [43, 50], three cases of 12.5 kg [54, 179, 181] and 2.53.0 kg in one case and one case series [33, 178] .
Reported maternal complications included cases of anaemia, hypertension, pre-eclampsia, urinary tract infection, graft loss due to haemorrhagic shock, sepsis, eclampsia, premature rupture of membranes and preterm labour [28] and two lupus flares [51] . Major congenital malformations were reported in 18 of 34 live births and 2 elective terminations. Where the type of malformation was specified, 14 of 15 cases included malformations typical for the previously described MMF embryopathy (including cleft lip and/or palate, microtia with aural atresia, micrognathia and ocular anomalies).
There were no reported cases of spontaneous miscarriage. There were no breastfeeding data. The only reports of long-term follow-up described one case who was small for age with otherwise normal development [43] and in another study reporting on three of six exposed children where one was normal, one had hearing aids and one had motor and speech delays [33] .
Paternal exposure
Three cohort studies [114, 168, 184] reported on outcomes from at least 72 pregnancies after paternal exposure to MMF. Overall, the quality of these studies was low, but they did not identify an increased risk of adverse foetal outcomes.
Recommendations for MMF in pregnancy and breastfeeding (i) MMF remains contraindicated during pregnancy and should not be given to women who are planning pregnancy (LOE 2À, GOR D, SOA 100%). (ii) In view of enterohepatic recirculation and prolonged half-life, treatment with MMF should be stopped at least 6 weeks before a planned pregnancy (LOE 3, GOR D, SOR 100%). (iii) No data exist on excretion into breast milk; breastfeeding is therefore not recommended (LOE 4, GOR D, SOA 99.5%). (iv) Based on very limited evidence, MMF is compatible with paternal exposure, but further studies to confirm this compatibility are warranted (LOE 2À, GOR D, SOA 98.9%).
IVIG
IVIG is compatible with pregnancy and breastfeeding [2, 3] . An additional 16 studies including 336 pregnancies exposed to IVIG were identified. The studies comprised 1 Cochrane review [9], 1 casecontrol study [185] , 10 cohort studies [26, 65, 66, 71, 105 , 186190], 1 case www.rheumatology.oxfordjournals.org series [30] and 3 case reports [47, 126, 191] . These pregnancies were identified from studies of 409 women with ARD, including APS, SLE and SS, as well as 284 patients with other diagnoses (including 128 with asymptomatic anti-Ro/La antibody positivity). All but two studies examined IVIG therapy in APS or prevention of CHB in anti-Ro/La-positive mothers. None of the papers specifically addressed the safety of IVIG; eight studies examined strategies for the prevention of AV block in foetuses at high risk [26, 30, 65, 66, 71, 105, 126, 188] and eight other studies examined strategies for the management of recurrent spontaneous abortion in APS and subfertility/infertility [9, 47, 185187, 189191]. Concomitant drug therapy included heparin, dexamethasone or prednisolone in many studies. A limited number of studies reported pregnancy duration and birthweight. In one study of 18 exposed pregnancies there were 3 preterm deliveries of <37 weeks and 4 of 18 were small for gestational age [26] . In six other studies (n = 58 exposed pregnancies) the average pregnancy duration was >36 weeks [47, 65, 66, 126, 185, 189] . In the remaining study (n = 17 pregnancies), the average gestation was 3334 weeks [71] . Mean birthweights were recorded in six studies (n = 95) and ranged from 2.65 to 3.27 kg [47, 66, 126, 185, 189, 190] . Pregnancy outcomes for IVIG were confounded by the condition requiring treatment.
Twelve maternal complications were reported, including one case of pre-eclampsia occurring in a study of patients with APS and recurrent miscarriages, 43 of whom received IVIG [187] . A total of 23 major congenital malformations from 102 live births were reported [26, 30, 71, 126, 187, 188] , largely in studies in which IVIG was used to treat CHB or foetal cardiomyopathy. In particular, 16 malformations listed under endomyocardial fibroelastosis occurred in a study of the use of IVIG and corticosteroids in the treatment of 20 maternal autoantibody-mediated cases of cardiomyopathy [71] . In addition, a case of DiGeorge syndrome occurred in a study of infertile mothers undergoing treatment with adalimumab, enoxaparin and/or corticosteroids depending on the immune profile, as well as IVIG [189] . Three first-trimester and two second-trimester pregnancy losses were recorded out of 43 IVIG exposures in a study of pregnancy outcome in patients positive for APS [187] .
There were no studies of breastfeeding. Three studies described long-term follow-up of 3442 months [66, 71, 126] . However, details are lacking except from one case of heart block in the Eliasson study, which also included eight neonatal deaths and was looking at the use of IVIG in foetal AV block.
The studies identified were focused on therapeutic efficacy rather than the safety of IVIG, hence all outcomes are confounded by use in patients with high-risk pregnancies. The number and type of maternal and foetal complications observed are compatible with known effects of the underlying maternal disease on pregnancy rather than being specific to IVIG. In particular, one small (n = 9) study found an improved outcome for foetuses treated with IVIG and steroids to treat maternal autoantibody-mediated cardiomyopathy [71] . The studies reviewed did not raise any new concerns to question the accepted safety of IVIG in pregnancy. None of the studies addressed the use of IVIG in breastfeeding or with paternal exposure.
Recommendations for IVIGin pregnancy and breastfeeding
(i) IVIG is compatible with pregnancy (LOE 1 ++, GOR A, SOA 100%). (ii) IVIG is compatible with breastfeeding (LOE 4, GOR D, SOA 98.9%). (iii) There is no evidence related to paternal exposure, but based on maternal compatibility, it is unlikely to be harmful (LOE 4, GOR D, SOA 98.9%).
Biologics
Biologic therapies are commonly used as second-line agents to treat various forms of ARD. They are recombinant proteins, most commonly monoclonal IgG1 antibodies directed against specific targets or fusion proteins containing the Fc portion of IgG1 joined to receptor-blocking proteins. The presence of the Fc region of IgG1 in the majority of these biologic agents is required for their active placental transfer, which does not take place until the 16 th week of pregnancy onwards. Due to the relative lack of evidence pertaining to biologics use for rheumatic disease while breastfeeding, five case series of biologics use for non-rheumatic disease while breastfeeding were also reviewed and included if relevant. Biologic drugs are often given alongside other DMARDs, and decisions regarding continuation of treatment should be made for each drug independently.
Anti-TNF-drugs
There are five biologic agents that inhibit TNF-a that are currently licenced to treat ARD: etanercept (ETA), IFX, adalimumab (ADA), golimumab (GOL) and certolizumab pegol (CZP). Three of these drugs (IFX, ADA and GOL) are monoclonal IgG1 directed against TNF-a, one (ETA) is a fusion protein of the TNF receptor joined to the Fc region of IgG1 and CZP is an antigen binding fragment (Fab 0 ) of a monoclonal anti-TNF-a antibody that lacks the Fc region of IgG1 and has been conjugated with polyethylene glycol. These drugs have different half-lives, bioavailability and rates of placental transfer that are relevant when considering their potential use in pregnancy.
The previous 20068 consensus recommendations advised avoidance of ETA, IFX and ADA in pregnancy and breastfeeding due to a lack of evidence rather than evidence of harm, and the 2010 BSR guidelines [192] (currently under revision) concur, unless the risks of stopping the treatment are perceived to be high. Further evidence has now accumulated predominantly from first-trimester exposure to these drugs, which do not cross the placenta until week 16 of pregnancy onwards. The majority of relevant studies show compatibility with pregnancy and a consensus statement considers anti-TNF-a drugs for treatment of IBD (IFX, ADA and CZP) to be low risk in the first and second trimester of pregnancy [192] .
A search for publications from 2008 onwards (since the last consensus) identified 5 cohort studies [103, 194197] , 8 case series [131, 198204] and 1 case report [205] of 265 IFX-exposed pregnancies; 3 cohort studies [21, 103, 194] , 3 case series [34, 200, 206] and 4 case reports [42, 45, 207, 208] of 100 ETA-exposed pregnancies; 4 cohort [21, 103, 189, 195] , 5 case series [33, 200, 202204 ] and 3 case reports [205, 209, 210] of 89 ADA-exposed pregnancies; and a case series of 10 CZP-exposed pregnancies [204] . In addition, two cohort studies [211, 212] , one case series [213] and one casecontrol study [130] reported combined outcomes from 201 pregnancies exposed to ETA, IFX, ADA and/or CZP. All of these studies examined TNFi use in patients with rheumatic disease or IBD. There remain no published studies of GOL in human pregnancy or breastfeeding.
These studies examined outcomes from 706 TNFiexposed pregnancies of patients with predominantly IBD but also rheumatic disease and two studies of nonautoimmune-mediated recurrent spontaneous miscarriage [189, 211] compared with 399 disease and 170 healthy control pregnancies. At least 349 exposures occurred in the first trimester and 252 in the second trimester. There were multiple confounders of concomitant therapies (including MTX, LEF and MMF) and active inflammatory disease. Of those studies describing pregnancy duration, birthweight, maternal complications and/ or miscarriages, the majority reported term deliveries, mean birthweights >3 kg, few maternal complications (which were mostly disease related) and a total of 56 of 474 first-trimester miscarriages and 8 of 474 second-/ third-trimester foetal loss. Therefore, no consistent adverse effects of any TNFi were observed. Similarly, although various major malformations were described, there were no consistent patterns of abnormalities and the incidence was not increased compared with the control groups. Interestingly, in a large casecontrol study, a lower incidence of preterm delivery (<37 weeks) was observed in 6.1% of 253 TNFi-treated IBD pregnancies compared with 9.1% of 318 non-TNFi-or thiopurineexposed IBD pregnancies [130] .
If TNFi therapy is given in the third trimester, live vaccines should be avoided in the infant, as a case of fatal TB-like disease has been reported after Bacillus CalmetteGué rin in an infant who was not breastfed but was exposed to IFX throughout pregnancy [214] . It is likely that very little drug is absorbed from breast milk.
Of the breastfeeding studies that we identified, ADA was detectible in breast milk (n = 2) but not in infant serum [203] , and both ETA (n = 3) as well as IFX (n = 3) were detectable in breast milk at very low levels [42, 201, 207, 208] , while IFX (n = 1) was undetectable in another study [199] , with no adverse effects detectable in any of these breastfed infants. In contrast, CZP was undetectable in longitudinal breast milk samples (five in the first month) taken from one patient [204] . None of these latter studies examined for the presence of drug in neonatal serum, and given the size of monoclonal antibodies, they are likely to be digested in the infant digestive tract.
There were long-term follow-up data on ETA to 9 months with no problems in 12 healthy children [42, 200, 206208] and up to 7 months in a case series of 11 children, with reports of hand-foot-mouth disease at 9 months in one infant and upper respiratory tract infections in two others [204] , as well as ADA to 1415 months [203] and CZP to 1 month [204] with no complications reported.
A study published after our final search of 56 firsttrimester exposures to TNFi (ETA, IFX and ADA) did not identify a significant increase in the risk of congenital malformations, foetal death or neonatal complications in pregnancies of women with chronic autoimmune disease compared with those who received TNFi before but not during pregnancy [129] .
Interestingly, data are emerging that TNFis have different rates of placental transfer with CZP (a pegylated Fab 0 fragment of an anti-TNF-a antibody) shown to have the lowest rates of placental transfer compared with other TNFis, consistent with its structure, which lacks the Fc component found in other monoclonals, and is compatible with pregnancy. A study of 31 pregnant women with IBD receiving IFX (n = 11), ADA (n = 10) or CZP (n = 10) throughout pregnancy found that concentrations of IFX and ADA, but not CZP, were higher in blood from infants at birth and their cord blood than in their mothers blood. The levels of CZP in infants and cord blood were <2 mg/ml. The median level of IFX in the cord blood was 160% that of the mother, the median level of ADA in the cord blood was 153% that of the mother and the median level of CZP in the cord blood was 3.9% that of the mother. The median time from last dose to delivery was 35 days for IFX, which then took up to 7 months for infant levels to become undetectable; 5.5 weeks for ADA, which took up to 11 weeks to become undetectable in the infant; and 19 days for CZP. No congenital anomalies or serious complications were reported in any of the children. This study provided clear evidence that IFX and ADA are transferred across the placenta and can be detected in infants at birth, and for up to 7 months afterwards in the case of IFX. In contrast, CZP had the lowest levels of placental transfer of the three drugs tested [204] . Two case studies have also shown low rates of placental transfer of ETA administered throughout pregnancy, with cord levels at delivery of 3.6% and 7.4% those of maternal serum in patients [42, 208] . Therefore, discontinuation of ADA, ETA and CZP at the end of the second trimester would ensure negligible or no drug is detectable in cord blood at delivery. For IFX however, its prolonged bioavailability and high rate of placental transfer mean that it may need to be stopped earlier in pregnancy for it to be undetectable in cord blood at delivery.
Recent data published in abstract form after our final search, highlighted by UCB Pharma through open consultation on this guideline, looked at the UCB Pharma global safety database for all cases of pregnancy exposures to CZP. As of September 2014, 625 CZP-exposed pregnancies had been reported; 579 were maternal, mostly first-trimester exposure, and 46 were paternal.
www.rheumatology.oxfordjournals.org Pregnancy outcomes were available for 339 of these pregnancies: 192 in women with Crohn's disease and 118 in women with rheumatic diseases. For the 118 pregnancies in women with rheumatic diseases, 83 (70%) resulted in a live birth, 17 (14%) in spontaneous miscarriage and 17 (14%) in elective termination. Congenital anomalies were reported in 12 babies among 254 live births following maternal CZP exposure (n = 132): 1 had 22q11.2 deletion syndrome, unilateral right kidney, hypospadias and inguinal hernia; 1 had congenital morbus Hirschsprung disease and club foot; and 10 were born with one of the following: anal fistula, left-sided vesicoureteric reflux, pyloric stenosis, cleft palate, club foot, polydactyly, right aortic arch with aberrant left subclavian artery, renal cyst (no treatment required), posterior ankyloglossia or diaphragmatic hernia. Based on these findings, CZP exposure was not considered to adversely affect pregnancy outcomes [215] .
Paternal exposure
Five cohort studies [21, 113, 147, 197, 216] , two case series [117, 119] , two case reports [140, 217] and a casecontrol study [118] reported on outcomes from 131 pregnancies after paternal exposure to IFX, ETA and ADA. Overall, the quality of these studies was low, but they did not identify an increased risk of adverse foetal outcomes. Furthermore, improved sperm motility was observed in 15 TNFi-treated patients with AS compared with 11 non-TNFi-treated patients with AS [218] . [103, 219, 220] , one case series [221] and four case reports [222225] on 173 RTX-exposed pregnancies that met our inclusion criteria. The majority of these exposures are accounted for in a report on pregnancy outcomes from the RTX global drug safety database in which most patients received the drug for non-rheumatic disease, including serious haematological disease and non-Hodgkin's lymphoma [219] . Where stated, the timing of RTX exposure varied from 6 to 22 months pre-conception in 8 pregnancies, 03 months pre-conception in 6 pregnancies and during pregnancy in 72 pregnancies. In the largest cohort study describing the RTX global drug safety database data on 153 patients with known pregnancy outcomes exposed to RTX before or during pregnancy, 90 resulted in live births, 33 in spontaneous miscarriage, 1 in second-/third-trimester foetal loss and 28 in elective termination. Twenty-two infants were born before 37 weeks, but none at <30 weeks, with one neonatal death at 6 weeks. Eleven neonates had haematological abnormalities, including transient neonatal lymphopenia or B cell depletion, and none of these neonates had corresponding infections, while infections were reported in four other neonates. Two congenital malformations were identified: clubfoot in one twin and cardiac malformation in a singleton birth. One maternal death from pre-existing autoimmune thrombocytopenia occurred [219] . Reported outcomes from other studies were pregnancy duration of 14 term deliveries, 2 at 3437 weeks and 3 at 3034 weeks; birthweights of 2.35 kg at 36 weeks, 2.42 at 37 weeks, mean 3.25 kg in four SLE pregnancies and 2.9 kg in a term Granulomatosis with Polyangitis pregnancy; maternal complications in four pregnancies related to maternal disease; and two congenital abnormalities, a case of oesophageal atresia (child born to a mother exposed to RTX for 12 months and alendronic acid for 6 months pre-conception) and a case of Turner syndrome diagnosed pre-RTX therapy [220225] . Long-term followup was reported from 11 months to 4.5 years in three children, one of whom had a prolonged QT interval in an anti-Ro-positive mother [224, 225] . Only one of these studies measured the B cell count at birth in twins born to a mother with RA given RTX 6 weeks pre-conception and found it to be normal [222] . Since Ostensen et al.
[3], case reports of RTX exposure in at least 15 other pregnancies of patients with non-rheumatic disease have been published. These studies reported reassuring pregnancy outcomes but found low B cells at birth in 6 of 11 children tested, 5 of whom were exposed to RTX in the second/ third trimester, while 5 of 6 children with pre-conception or first-trimester RTX exposure had normal B cell levels, reviewed in Hyrich and Verstappen [226] . No human breastfeeding data studies were identified.
Given that RTX does not cross the placenta until week 16 of pregnancy, reports of satisfactory pregnancy outcomes are accumulating and its maximum plasma halflife is 35 days, it is reasonable to shorten the interval between stopping the drug and conception to at least 6 months from the manufacturer's recommendation of 12 months.
A cohort study [219] reported on outcomes from 11 pregnancies after paternal exposure to RTX. The quality of this study was low, with no information provided about paternal dose of RTX, maternal health or concomitant medications in exposed pregnancies. There were seven live births with no complications, two miscarriages and two ongoing pregnancies.
Recommendations for RTX in pregnancy and breastfeeding (i) There remains insufficient evidence to be confident that RTX is compatible with pregnancy and it should be stopped 6 months before conception. [227] . Of 32 RA patients, 26 received TCZ/ MTX combination therapy and 6 received TCZ monotherapy or a concomitant DMARD other than MTX. Elective termination of pregnancy was performed in 13 cases, 7 aborted spontaneously (5 received concomitant MTX at conception) and 11 patients (2 with TCZ monotherapy and 9 with concomitant MTX) delivered 10 healthy new-borns at term. One infant died of respiratory distress syndrome 3 days after emergency caesarean section for intrapartum foetomaternal haemorrhage due to placenta praevia. The outcome was unknown for two pregnancies.
Recommendations for TCZ in pregnancy and breastfeeding (i) There are insufficient data and TCZ should be stopped at least 3 months pre-conception, but unintentional exposure early in the first trimester is unlikely to be harmful (LOE 3, GOR D, SOA 96.8%).
(ii) There are no data upon which to base a recommendation for TCZ use in breastfeeding (SOA 99.5%). (iii) There are no data relating to paternal exposure to TCZ, but it is unlikely to be harmful (LOE 4, GOR D, SOA 97.9%).
Anakinra
Anakinra is a recombinant form of human interleukin-1 receptor antagonist with a high molecular weight that was not found to cross ex vivo full-term human placentae [228] . We identified data from five pregnancies in a cohort study [103] , case series [229] and case report [230] . In three patients with adult-onset Still's disease there were no appreciable adverse effects on pregnancy [229, 230] . In a cohort study of 393 pregnancies identified from 34 169 women of reproductive age with RA, one patient in the elective abortion group (n = 37) was taking anakinra, which was not statistically significant compared with the successful delivery group (n = 281 pregnancies), in which one patient was also on anakinra [103] . There were no human breastfeeding data, and no studies of paternal exposure were identified.
Recommendations for anakinra in pregnancy and breastfeeding (i) There is limited evidence on which to base a recommendation for anakinra in pregnancy, but unintentional exposure in the first trimester is unlikely to be harmful (LOE 2À, GOR D, SOA 96.8%). (ii) There are no data upon which to base a recommendation for anakinra use in breastfeeding (SOA 100%). (iii) There are no data relating to paternal exposure to anakinra, but it is unlikely to be harmful (LOE 4, GOR D, SOA 98.9%).
Abatacept
ABA is a fusion protein containing the Fc region of IgG1 fused to the extracellular domain of CTLA-4, therefore it is able to cross the placental barrier from about week 16 onwards. Animal studies published in abstract form, conducted in the absence of concomitant medications (such as low-dose MTX), have not shown any adverse effects of ABA on fertility or foetal development [231] . There remains very limited published human pregnancy experience with ABA. We identified one case series [133] and one case report [225] reporting on three pregnancies exposed to ABA in the first trimester. These pregnancies were all confounded by concomitant MTX use. There were two (one spontaneous and one elective) first-trimester miscarriages [133] and a full-term delivery of a healthy infant followed to 3.5 years of age with no complications [225] . Although it did not meet our search inclusion criteria, a review article has reported pregnancy outcomes from eight patients in the double-blind and open-label phases of studies of ABA [231] . All of these patients were on concomitant MTX (n = 7) or LEF (n = 1). Spontaneous first-trimester abortion occurred in three patients (two of whom www.rheumatology.oxfordjournals.org had a prior history of spontaneous abortion) and elective abortion was performed in two patients. The remaining three patients were still pregnant at the time the study report was written. This review article also described the spouse of a man treated with ABA, who became pregnant and delivered a healthy baby [231] .
Recommendations for ABA in pregnancy and breastfeeding (i) There are insufficient data to recommend ABA in pregnancy, but unintentional exposure early in the first trimester is unlikely to be harmful (LOE 3, GOR D, SOA 98.9%). (ii) There are no data upon which to base a recommendation for ABA use in breastfeeding (SOA 100%). (iii) There are no data relating to paternal exposure to ABA, but it is unlikely to be harmful (LOE 4, GOR D, SOA 98.9%).
Belimumab
Belimumab (BEL) is a fully humanized monoclonal IgG1 that inhibits B cell activating factor. It is licensed for use in the UK but does not have National Institute for Health and Clinical Excellence approval. We did not identify any publications that met our search criteria on use of this drug in human pregnancy. A recent review article summarized human pregnancy data from unintended pregnancies that occurred during the manufacturer's placebo-controlled phase 2 and 3 studies of this drug in patients with SLE [232] . In these studies, patients received BEL and concomitant therapy (corticosteroids, immunosuppressives, antimalarials, NSAIDs or a combination thereof); when each pregnancy was discovered, BEL was stopped immediately and the patient removed from the trial. A total of 83 pregnancies had known outcomes: 24% elective terminations, 27.7% spontaneous abortions and 42% live births. Of the three congenital anomalies (rate of 3.6%) that developed in these pregnancies, one was a chromosomal translocation also found in the mother, and thus was unrelated to BEL. The BEL pregnancy registry has been set up to study the health of pregnant women receiving BEL within 4 months prior to and/or during pregnancy (http://clinicaltrials.gov/ show/NCT01532310). The first two pregnancy outcomes from the BEL registry have recently been reported in abstract form [233] .
Given the paucity of information, further unpublished data from the BEL pregnancy registry was obtained describing known outcomes (as of 8 September 2014) from a total of 118 SLE pregnancies: 28% elective terminations and 28.8% spontaneous abortions, all with no apparent congenital anomaly; 37.3% live healthy births; and 4.2% live births with congenital anomaly, although no specific pattern was observed [234] .
Recommendations for BEL in pregnancy and breastfeeding (i) There are insufficient data to recommend BEL in pregnancy or breastfeeding, but unintentional exposure early in the first trimester is unlikely to be harmful (LOE 3, GOR D, SOA 100%). (ii) There are no data upon which to base a recommendation for BEL use in breastfeeding (SOA 100%). (iii) There are no data relating to paternal exposure to BEL, but it is unlikely to be harmful (GOR D, SOA 98.9%).
Applicability and Utility
Implementation
Awareness of these guidelines will aid clinical practitioners and patients in decision-making and will be raised through presentation at local, regional and national meetings. No barriers to implementation of these guidelines are anticipated.
Key standards of care
Ideally patients with rheumatic disease should receive tailored pre-pregnancy counselling and then be reviewed during pregnancy and the 4 month post-partum period by clinical practitioners with expertise in the management of rheumatic disease in pregnancy, in addition to their routine obstetric care. They should have access to written information on relevant medications in pregnancy and breastfeeding that is accurate and allows them to make informed decisions regarding the compatibility of certain drugs in pregnancy.
Future research agenda
The limitation of current evidence highlights the need for a national pregnancy registry for patients with rheumatic disease, as currently exists for women with epilepsy. All women with rheumatic disease who become pregnant would be eligible to register, whether or not they are on anti-rheumatic treatment. The prospective pregnancy outcome data would then be published to display information on outcomes such as miscarriage and congenital anomalies in patients treated with anti-rheumatic therapy. These data would also be used to answer specific questions such as when to stop MTX pre-conception and the compatibility of TNFi in breastfeeding. Data relating to the impact of paternal exposure to these drugs (both fertility and male-mediated teratogenicity), as well as breastfeeding exposure, are particularly limited, and further research in these areas are urgently required.
Mechanism for audit of the guideline
An audit pro forma to assess compliance with these guidelines is available on the British Society for Rheumatology website.
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Derivation of summary data
Numerical data are therefore collated only from papers where the relevant outcome was clearly quantified and each column reports as follows. Studies (type and number): all included studies provide some qualitative or quantitative information on the safety of the relevant drug in pregnancy. Pregnancy exposures (exposures per trimester): total number of pregnancy exposures to the drug of interest, collated from all studies where this information was quantified. Trimester in which drug exposure occurred is not specified in all papers, hence the numbers given here are the minimum exposures in the first and second/third trimesters. Live births: total number of live births from all studies where this information was reported specifically for exposure to the drug of interest (studies where quantitative outcomes particular to the drug of interest cannot be deduced from the manuscript are not included here). Spontaneous miscarriages/total pregnancy outcomes: rate of spontaneous miscarriage collated from studies where both live births and foetal/ neonatal deaths (miscarriages, live births, still births and elective terminations) have been quantified (studies reporting on live birth outcomes only are not included here). Pregnancy duration/birthweight: summarized from all papers where quantitative or qualitative information specific to the drug of interest was provided. Major malformations/total births: number of babies with a major malformation, collated from studies where this information was specifically quantified for the drug of interest. However, in a few cases it is not clear whether two or more major malformations occurred in a single baby or across several babies, in which case the total number of malformations is included here (e.g. 3 malformations in a cohort of 100 live births: if it is specified 1 baby with 3 major malformations, and 99 babies without malformations, this is presented as 1/100, whereas if it is not clear whether those 3 malformations were in 3 separate children or all in 1 child, it is presented as 3/100).
